Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

udy, concluding that bavituximab has demonstrated acceptable safety and a predictable PK profile and that a maximum tolerated dose was not reached even at the highest planned dose level. The majority of adverse events reported were mild or moderate in nature.

"The quality of the results generated to date in each of our three ongoing Phase II bavituximab cancer trials is very promising," said Steven W. King, president and CEO of Peregrine. "Our oral presentation today at ASCO exemplifies the heightened interest the bavituximab cancer program is receiving from both clinical researchers and potential partners, and we look forward to reporting on progress and additional results from all three of our Phase II bavituximab studies over the rest of the year."

About Phosphatidylserine (PS)-Targeting Therapies

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, ... Geography Trend and Forecast (2011 - 2016)," analyzes ... and studies the major market drivers, restraints, and opportunities ... Asia. , The global chocolate market is expected to ... 2016 at an estimated CAGR of 2.7% from 2011 ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... 21-1/2 hours of great entertainment and powerful appeals, the final ... Lewis MDA Telethon which raised $58,919,838 in contributions and ... Muscular Dystrophy Association.   "I,m heartened by the ... they themselves are likely struggling financially," said Lewis.  "People see ...
... COLUMBIA, Md., Sept. 3 The Maryland Stem Cell ... Stem Cell Research Symposium in partnership with the National ... Standards and Technology (NIST) on Wednesday, Sept. 22, 2010. ... Groundbreaking Life Science Research," will be held at the ...
... - 2015) -... -- DALLAS, Texas, September 3, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:MDA Telethon Exceeds Expectations 2Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 2Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 4New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 5New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 6New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 7New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 8
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
(Date:10/14/2014)... tumors scavenge and hoard copper that is an essential ... a fatal weakness. , Researchers at Duke Medicine ... by delivering a trove of copper along with a ... the mineral, leaving non-cancer cells healthy. , The combination ... other uses, could soon be tested in clinical trials ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... would overheat and die. In a recent paper in the journal ... team of researchers explored the ultimate origin of this sticky, stinky ... his team used a system to make all of the sweat ... green fluorescent protein (GFP), which is visible under ultraviolet light. ...
... the first evidence that coral itself may play an ... discovered that the coral animalnot just its algal symbiontmakes ... in many ways, ranging from cellular protection in times ... clouds to form. These findings have been published ...
... combination of the herbicide atrazine and a fungal disease ... a University of South Florida laboratory, which has been ... Biologist Jason Rohr said the new findings show that ... when the frogs were challenged with a chytrid fungus, ...
Cached Biology News:USC researcher learns how to break a sweat 2Coral chemicals protect against warming oceans 2Early-life exposure of frogs to herbicide increases mortality from fungal disease 2
... have been many modifications to the original formulas ... solutions still play an important role in tissue,culture. ... pH and osmotic balance in the medium and ... inorganic ions, is as valuable today as when ...
Request Info...
... LXQ linear ion trap mass spectrometer enables ... laboratory., The LXQ linear ion trap mass ... proteomic applications, delivering the fast cycle time ... ion trap at an attractive price. ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: